Opendata, web and dolomites

SUMMIT SIGNED

Stepping Up mRNA Mutanome Immunotherapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SUMMIT project word cloud

Explore the words cloud of the SUMMIT project. It provides you a very rough idea of what is the project "SUMMIT" about.

genetic    clinical    immune    cancers    clones    single    defects    immunity    outgrowth    compatible    patients    neoepitope    vaccines    mrna    full    mere    variants    spotlight    trial    presentation    deciphering    treatments    tackled    directed    antibodies    combination    resistance    care    hallmark    realization    individual    scientific    interdisciplinary    industrial    showed    vaccination    solving    protocols    pioneered    cancer    immunosuppression    counteracting    cells    vision    heterogeneous    scarcity    exhaustion    repertoire    potent    medical    personalized    memory    unaffected    acute    mechanisms    treatment    cell    preclinical    patient    health    mobilizing    spectrum    extensive    close    heterogeneity    standards    vaccinated    lived    drugs    countermeasures    unaccounted    antigen    discovery    inform    immunotherapy    nk    tumors    building    efficacy    fundamentally    rational    mediated    drug    mutanome    effector    mutations    algorithms    ignite    mechanism    efficient    vaccine    clonal    first    prediction    universal    disruptive    point    translation    human    constraints    wave    escape    seamless    technological    eliciting    strategies    moved    aberrations    tumor    drive   

Project "SUMMIT" data sheet

The following table provides information about the project.

Coordinator
TRON - TRANSLATIONALE ONKOLOGIE ANDER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ GEMEINNUTZIGE GMBH 

Organization address
address: FREILIGRATHSTRASSE 12
city: MAINZ
postcode: 55131
website: http://www.tron-mainz.de/

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 2˙482˙500 €
 EC max contribution 2˙482˙500 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2017-ADG
 Funding Scheme ERC-ADG
 Starting year 2018
 Duration (year-month-day) from 2018-08-01   to  2023-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    TRON - TRANSLATIONALE ONKOLOGIE ANDER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ GEMEINNUTZIGE GMBH DE (MAINZ) coordinator 2˙482˙500.00

Map

 Project objective

Immunotherapy is expected to fundamentally change the treatment of cancer patients. Personalized vaccines eliciting immune responses against individual cancer mutations have moved into the spotlight. We have pioneered the field and moved ´cancer mutanome vaccines´ from a mere vision into a disruptive medical concept compatible with current standards of drug development and health care practice. Solving key scientific and technological challenges and building on extensive preclinical studies, we showed in a first-in-human trial potent tumor-directed immunity in every single vaccinated patient, and clinical activity of a novel mRNA-based mutanome vaccine. Given that mutations are a hallmark of cancer, mRNA mutanome vaccines are universal drugs the efficacy of which are unaffected by the cancer type. The aim of this proposal is to ignite the next wave of advancement by addressing four key constraints challenging a full clinical realization of such vaccines. We will address the scarcity of point mutations in many tumors by extending neoepitope discovery to the full spectrum of genetic aberrations. Cancers are heterogeneous and outgrowth of clones unaccounted for by the vaccine is an efficient escape mechanism. We will develop neoepitope prediction algorithms deciphering clonal heterogeneity to inform rational vaccine design and countermeasures against selection of target escape variants. Tumor cell resistance to vaccine-induced T cells due to antigen presentation defects will be addressed by developing strategies for mobilizing the full repertoire of immune effector mechanisms, including antibodies and NK cells. T-cell exhaustion will be tackled by vaccination protocols promoting long-lived memory responses and by combination treatments counteracting tumor-mediated immunosuppression. Finally, we will drive the seamless clinical translation of the scientific findings by close interdisciplinary collaboration with strong and established clinical and industrial partners.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SUMMIT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SUMMIT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

evolSingleCellGRN (2019)

Constraint, Adaptation, and Heterogeneity: Genomic and single-cell approaches to understanding the evolution of developmental gene regulatory networks

Read More  

RODRESET (2019)

Development of novel optogenetic approaches for improving vision in macular degeneration

Read More  

IMMUNOTHROMBOSIS (2019)

Cross-talk between platelets and immunity - implications for host homeostasis and defense

Read More